DUX4L23: A Potential Drug Target and Biomarker for Double Homeobox 4-Like 23

Target Name: DUX4L23

NCBI ID: G102723472

DUX4L23

Other Name(s): Double homeobox 4 like 23 (pseudogene) | double homeobox 4 like 23 (pseudogene)

DUX4L23: A Potential Drug Target and Biomarker for Double Homeobox 4-Like 23

Double homeobox 4-like 23 (DUX4L23) is a gene that encodes a protein with unique structural features, which is highly conserved across various species, including humans. The protein encoded by DUX4L23 is involved in various cellular processes, including cell adhesion, migration, and invasion. It is also associated with various diseases, including cancer and neurodegenerative disorders.

Recent studies have identified DUX4L23 as a potential drug target and biomarker for various diseases. In this article, we will provide an overview of DUX4L23, its functions, and potential therapeutic applications.

Function and Significance of DUX4L23

DUX4L23 is a member of the homeobox gene family, which is characterized by a specific DNA binding motif called HEX. The HEX motif is composed of a series of conserved amino acids that form a distinct domain that is responsible for the protein's unique structure and function.

DUX4L23 is involved in various cellular processes, including cell adhesion, migration, and invasion. It is a critical regulator of cell-cell adhesion, which is a crucial aspect of tissue repair and regeneration. In addition, DUX4L23 is involved in the regulation of cell migration and invasion, which are essential processes for the growth and development of tissues.

DUX4L23 has also been linked to various diseases, including cancer and neurodegenerative disorders. It is a potential biomarker for several diseases, including pancreatic cancer, colorectal cancer, and neuroblastoma.

Potential Therapeutic Applications of DUX4L23

DUX4L23 has the potential to serve as a drug target for various diseases. One of the primary targets for DUX4L23 is the regulation of cell-cell adhesion, which is crucial for tissue repair and regeneration.

Studies have shown that DUX4L23 can be inhibited using small molecules, which can lead to the dissociation of cells from adhesion sites. This results in the loss of cell-cell adhesion, which can have therapeutic implications for diseases where cell-cell adhesion is abnormal.

In addition to its potential as a drug target, DUX4L23 has also been identified as a potential biomarker for several diseases, including cancer and neurodegenerative disorders. The detection and quantification of DUX4L23 expression may provide valuable information for the diagnosis and prognosis of these diseases.

Conclusion

DUX4L23 is a gene that encodes a protein with unique structural features that are highly conserved across various species. It is involved in various cellular processes, including cell adhesion, migration, and invasion. In addition, DUX4L23 is associated with various diseases, including cancer and neurodegenerative disorders.

Recent studies have identified DUX4L23 as a potential drug target and biomarker for various diseases. The regulation of cell-cell adhesion and the identification of DUX4L23 as a potential therapeutic target may have significant implications for the treatment of these diseases. Further research is needed to fully understand the functions and potential therapeutic applications of DUX4L23.

Protein Name: Double Homeobox 4 Like 23 (pseudogene)

The "DUX4L23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DUX4L23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets